Fuji Pharma Co., Ltd. (4554.T)
JPY 1362.0
(0.74%)
JPY 1362.0
(0.74%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 40.88 Billion JPY | 15.42% |
| 2022 | 35.42 Billion JPY | 4.22% |
| 2021 | 33.99 Billion JPY | 0.58% |
| 2020 | 33.79 Billion JPY | -6.85% |
| 2019 | 36.27 Billion JPY | -4.3% |
| 2018 | 37.9 Billion JPY | 7.13% |
| 2017 | 35.38 Billion JPY | 3.38% |
| 2016 | 34.22 Billion JPY | 8.05% |
| 2015 | 31.68 Billion JPY | 8.44% |
| 2014 | 29.21 Billion JPY | 16.05% |
| 2013 | 25.17 Billion JPY | 16.97% |
| 2012 | 21.52 Billion JPY | -0.47% |
| 2011 | 21.62 Billion JPY | 9.75% |
| 2010 | 19.7 Billion JPY | 14.54% |
| 2009 | 17.2 Billion JPY | 15.13% |
| 2008 | 14.94 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 10.64 Billion JPY | -0.97% |
| 2024 Q1 | 10.74 Billion JPY | -5.79% |
| 2024 Q3 | 11.76 Billion JPY | 10.57% |
| 2023 Q3 | 10.25 Billion JPY | 11.14% |
| 2023 Q4 | 11.4 Billion JPY | 11.21% |
| 2023 FY | 40.88 Billion JPY | 15.42% |
| 2023 Q1 | 9.99 Billion JPY | 11.61% |
| 2023 Q2 | 9.22 Billion JPY | -7.67% |
| 2022 Q2 | 8.28 Billion JPY | -12.34% |
| 2022 Q1 | 9.44 Billion JPY | 11.23% |
| 2022 FY | 35.42 Billion JPY | 4.22% |
| 2022 Q4 | 8.95 Billion JPY | 2.42% |
| 2022 Q3 | 8.74 Billion JPY | 5.6% |
| 2021 Q2 | 7.98 Billion JPY | -14.13% |
| 2021 FY | 33.99 Billion JPY | 0.58% |
| 2021 Q1 | 9.29 Billion JPY | 4.51% |
| 2021 Q3 | 8.22 Billion JPY | 2.99% |
| 2021 Q4 | 8.49 Billion JPY | 3.3% |
| 2020 Q1 | 8.96 Billion JPY | 0.15% |
| 2020 FY | 33.79 Billion JPY | -6.85% |
| 2020 Q2 | 7.93 Billion JPY | -11.5% |
| 2020 Q3 | 7.99 Billion JPY | 0.72% |
| 2020 Q4 | 8.89 Billion JPY | 11.26% |
| 2019 Q4 | 8.95 Billion JPY | 1.29% |
| 2019 FY | 36.27 Billion JPY | -4.3% |
| 2019 Q1 | 10.27 Billion JPY | 2.41% |
| 2019 Q2 | 8.2 Billion JPY | -20.19% |
| 2019 Q3 | 8.84 Billion JPY | 7.76% |
| 2018 Q2 | 8 Billion JPY | -19.61% |
| 2018 Q1 | 9.95 Billion JPY | 6.25% |
| 2018 Q3 | 9.91 Billion JPY | 23.83% |
| 2018 Q4 | 10.03 Billion JPY | 1.27% |
| 2018 FY | 37.9 Billion JPY | 7.13% |
| 2017 FY | 35.38 Billion JPY | 3.38% |
| 2017 Q3 | 8.69 Billion JPY | 3.57% |
| 2017 Q2 | 8.39 Billion JPY | -6.05% |
| 2017 Q1 | 8.93 Billion JPY | -2.92% |
| 2017 Q4 | 9.37 Billion JPY | 7.81% |
| 2016 Q4 | 9.2 Billion JPY | 12.32% |
| 2016 FY | 34.22 Billion JPY | 8.05% |
| 2016 Q1 | 8.92 Billion JPY | 2.85% |
| 2016 Q2 | 7.9 Billion JPY | -11.4% |
| 2016 Q3 | 8.19 Billion JPY | 3.58% |
| 2015 Q3 | 7.54 Billion JPY | 1.99% |
| 2015 FY | 31.68 Billion JPY | 8.44% |
| 2015 Q1 | 8.06 Billion JPY | -2.27% |
| 2015 Q2 | 7.39 Billion JPY | -8.36% |
| 2015 Q4 | 8.68 Billion JPY | 15.12% |
| 2014 FY | 29.21 Billion JPY | 16.05% |
| 2014 Q4 | 8.25 Billion JPY | 21.69% |
| 2014 Q3 | 6.78 Billion JPY | -6.75% |
| 2014 Q2 | 7.27 Billion JPY | 5.36% |
| 2014 Q1 | 6.9 Billion JPY | -3.41% |
| 2013 Q4 | 7.14 Billion JPY | 18.54% |
| 2013 Q3 | 6.03 Billion JPY | 0.2% |
| 2013 FY | 25.17 Billion JPY | 16.97% |
| 2013 Q2 | 6.01 Billion JPY | 0.67% |
| 2013 Q1 | 5.97 Billion JPY | -2.12% |
| 2012 Q1 | 4.85 Billion JPY | -17.16% |
| 2012 Q4 | 6.1 Billion JPY | 8.4% |
| 2012 Q3 | 5.63 Billion JPY | 14.36% |
| 2012 FY | 21.52 Billion JPY | -0.47% |
| 2012 Q2 | 4.92 Billion JPY | 1.54% |
| 2011 Q4 | 5.85 Billion JPY | 16.66% |
| 2011 Q1 | 5.48 Billion JPY | 10.21% |
| 2011 FY | 21.62 Billion JPY | 9.75% |
| 2011 Q3 | 5.02 Billion JPY | -4.5% |
| 2011 Q2 | 5.25 Billion JPY | -4.19% |
| 2010 Q4 | 4.97 Billion JPY | -3.41% |
| 2010 Q2 | 4.34 Billion JPY | -16.87% |
| 2010 Q3 | 5.15 Billion JPY | 18.71% |
| 2010 Q1 | 5.22 Billion JPY | 1.83% |
| 2010 FY | 19.7 Billion JPY | 14.54% |
| 2009 Q1 | 3.9 Billion JPY | 0.0% |
| 2009 Q2 | 3.67 Billion JPY | -6.01% |
| 2009 Q3 | 4.48 Billion JPY | 22.21% |
| 2009 Q4 | 5.13 Billion JPY | 14.27% |
| 2009 FY | 17.2 Billion JPY | 15.13% |
| 2008 FY | 14.94 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 34.206% |
| Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.041% |
| Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 87.001% |
| Shionogi & Co., Ltd. | 435.08 Billion JPY | 90.602% |
| Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | -428.389% |
| Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 72.42% |
| Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 43.244% |
| Eisai Co., Ltd. | 741.75 Billion JPY | 94.488% |
| Morishita Jintan Co., Ltd. | 12.4 Billion JPY | -229.591% |
| Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 71.145% |
| Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 60.258% |
| Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 26.201% |
| Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | -32.981% |
| Tsumura & Co. | 150.84 Billion JPY | 72.893% |
| Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 45.899% |
| Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 25.164% |
| Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 82.061% |
| Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 46.003% |
| KYORIN Holdings, Inc. | 119.53 Billion JPY | 65.792% |
| Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | -711.29% |
| Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 12.807% |
| SymBio Pharmaceuticals Limited | 5.58 Billion JPY | -631.505% |
| MedRx Co., Ltd | 26 Million JPY | -157165.385% |
| Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | -272.065% |
| Solasia Pharma K.K. | 617 Million JPY | -6527.066% |
| Modalis Therapeutics Corporation | - JPY | -Infinity% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 34.935% |
| Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 76.881% |
| Cyfuse Biomedical K.K. | 61.11 Million JPY | -66808.3% |
| Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 97.231% |
| Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | -84.733% |